The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Dual targeting of RAF-MEK-ERK and PI3K-AKT-mTOR pathways in RAS-mutant cancers: Preclinical insights and institutional experience from a clinical trial of binimetinib (MEK162) plus BYL719.
Udai Banerji
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Alan David Smith
No relevant relationships to disclose
Andrea Zivi
No relevant relationships to disclose
David Lorente
No relevant relationships to disclose
Karim Rihawi
No relevant relationships to disclose
Nina Tunariu
No relevant relationships to disclose
Adam Stewart
No relevant relationships to disclose
Parames Thavasu
No relevant relationships to disclose
Audrey Kaag
Employment or Leadership Position - Novartis
Rajkumar Radhakrishnan
Employment or Leadership Position - Novartis
Heiko Maacke
Employment or Leadership Position - Novartis
L Rhoda Molife
No relevant relationships to disclose
Stanley B. Kaye
No relevant relationships to disclose
Johann Sebastian De Bono
No relevant relationships to disclose